Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APP13007 Phase 2a in Post-Cataract Inflammation
NCT04089735Phase 2Completed
- Sponsor
- Formosa Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Nanoparticles, Implantable Devices, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GPN00833 in post-operative ocular inflammation and post-operative ocular pain (6 arms), sponsored by Formosa Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at Day 28, Intraocular Pressure Change From Baseline at Day 22 and 3 more. Started Aug 2019; status: completed.
02
Drugs
GPN00833
03
Conditions
post-operative ocular inflammationpost-operative ocular pain
Beyond the preview
Go deeper on NCT04089735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089735.